Date | Price Target | Rating | Analyst |
---|---|---|---|
11/30/2021 | $4.00 | Buy | Lake Street |
Lake Street initiated coverage of Ensysce Biosciences with a rating of Buy and set a new price target of $4.00
D - Ensysce Biosciences, Inc. (0001716947) (Filer)
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
424B5 - Ensysce Biosciences, Inc. (0001716947) (Filer)
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13D/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
~ PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has made available two video segments from its August 8th symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium emphasized opioid use worldwide, the current landscape for treating severe pain, including post-surgical and cancer pain treatment, and discussed Ensys
SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale of an aggregate of 3,553,194 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.47 per share (or common stock equivalent in lieu thereof) in a registered direct offering. The Company also entered into definitive agreemen
New York, NY, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ:ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks. The update note is available here. Ensysce August 2024 Note Highlights from the note include: NIH and NIDA Award $14 Million Grant to Ensysce Biosciences for Opioid Development with Overdose Protection: Ensysce Biosciences has received a $14 million grant from the National Institutes of Health (NIH) and the Natio
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are proud of the significant progress Ensysce has made in 2023 both operationally and clinically for our lead pain therapeutic, PF614, and our overdose protection product, PF614-MPAR.
~ Reminder: Corporate Update Conference Call to be Held Today at 11:00am ET ~SAN DIEGO, CA / ACCESSWIRE / April 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. As a reminder, the Company will be holding a corporate update conference call today, Tuesday, April 11, 2023, at 11:00am ET.Corporate Update Conference CallDate: Tuesday, April 11, 2023Time: 11:00am ETU.S. Dial-in: 1-877-407-0792International Dial-in: 1-201-689-8263Webcast: ENSC Corporate Upd
SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, excl
SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company's clinical advisory board.Dr. Osman, a highly versatile board-certified neurologist, migraine and pain specialist, has over ten years of experience in both R&D and
SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced that Lee Rauch has been appointed to the Company's board of directors. Ms. Rauch, an experienced Chief Executive Officer and Strategy Advisor, has served both public and private companies. During her near 40-year career, Ms. Rauch successful built companies ranging in focus from pre-clinical research to advanced clinical development, took
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. Dr. Pestano has worked through her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. Dr. Pestano received her PhD from Tuffs University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston. Her early research was vi